In a major leap for child health, a new malaria drug for newborns has been approved for use across Africa.
The drug, called Coartem Baby also known as Riamet Baby in some regions is the first malaria treatment designed specifically for babies under 4.5kg.
Until now, infants infected with malaria were forced to use older children’s medication, increasing the risk of overdose and side effects.
This approval closes a deadly gap in malaria care for newborns one that experts say has long endangered Africa’s youngest.
The medicine was developed by Swiss pharma giant Novartis, in partnership with the Medicines for Malaria Venture (MMV).
Swiss authorities approved the treatment after successful trials in eight African countries, with wide rollout expected in the coming weeks.
According to the World Health Organization (WHO), malaria killed about 597,000 people in 2023. Over 75% were children under five.
“This is a milestone,” said Novartis CEO Vas Narasimhan. “Now even the smallest babies can get safe, proven treatment.”
Diaspora Digital Media learnt that the drug will be distributed mostly at cost or not-for-profit, backed by funding from the UK, Switzerland, the Netherlands, World Bank, and others.
Dr. Martin Fitchet, CEO of MMV, said the approval provides a lifeline to an often-neglected group.
“Malaria is one of the world’s deadliest diseases. This gives hope to thousands of families,” he said.
The Public health expert Dr. Marvelle Brown called it a “game-changer” for Africa’s fight against child mortality.
“With over 76% of malaria deaths among kids under five, this drug is vital,” she added.
Babies with sickle cell disease, who are especially vulnerable, stand to benefit greatly from the treatment.
Health officials and humanitarian agencies believe the rollout could save tens of thousands of lives each year.
The approval comes amid renewed global urgency to tackle health inequality and reduce preventable child deaths across developing nations.
